Symbol | Exchange | Currency |
---|
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
11,380.00 | 114.00 | 113.00 | +11,266.80 | +1,000.00% | 445.90K | London | |||
52.55 | 53.70 | 50.30 | +0.75 | +1.45% | 7.42M | London | |||
414.30 | 416.30 | 407.40 | +4.20 | +1.02% | 10.46M | London | |||
422.00 | 422.00 | 421.00 | +2.00 | +0.47% | 92.54K | London | |||
1,152.50 | 1,154.00 | 1,133.50 | +17.50 | +1.54% | 3.39M | London | |||
4,473.00 | 4,571.00 | 4,454.00 | -63.0 | -1.39% | 985.51K | London | |||
117.84 | 121.16 | 117.84 | -2.80 | -2.32% | 10.52M | London | |||
798.80 | 803.60 | 790.40 | +7.20 | +0.91% | 18.84M | London | |||
3,096.00 | 3,100.00 | 3,057.00 | +14.0 | +0.45% | 382.86K | London | |||
480.80 | 499.00 | 479.20 | -5.70 | -1.17% | 1.59M | London | |||
2,286.00 | 2,348.00 | 2,274.00 | -61.0 | -2.60% | 157.13K | London | |||
0.31 | 0.34 | 0.34 | -0.025 | -7.46% | 9.95M | London | |||
29.15 | 29.35 | 28.20 | +0.20 | +0.69% | 1.01M | London | |||
122.28 | 122.88 | 120.02 | +1.26 | +1.04% | 38.46M | London | |||
263.70 | 264.20 | 261.50 | +1.60 | +0.61% | 16.59M | London |